Thermo Fisher Scientific has enrolled the first patient in a prospective observational registry designed to generate real-world evidence on obesity treatments. The regirstry includes anti-obesity medications and GLP-1 receptor agonists. The PPD CorEvitas Obesity Registry will collect longitudinal data from both clinicians and patients. It will track how therapies are used in practice, how long…
The weight-loss drug market: overhyped or justified?
The obesity drug market has seen a surge of interest recently, largely thanks to the popularity of glucagon-like peptide-1 (GLP-1) drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro. The explosion in interest in the drug class has fueled the stock prices of Novo and Lilly, which both have multiple GLP-1 drugs in their portfolios. …

